Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 18,278 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Controlled Group Clear all

Conditions: Anemia, Unexplained Anemia (UAE)
Interventions: iron sucrose; Drug
Lead sponsor: Duke University; Other
Eligibility: 65 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Chicago, Illinois • Baltimore, Maryland • Cleveland, Ohio + 1 more

Conditions: Myelopathy, Compressive, Radiculopathy, Cervical, C5 Palsy
Interventions: Bilateral Cervical Keyhole Foraminotomy, Cervical Decompression; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Human Papillomavirus Vaccines
Interventions: Practice Facilitation, Education, Audit and Feedback, Communication Strategy; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: DRESS Syndrome, Drug-Induced Hypersensitivity Syndrome
Interventions: Cyclosporine, Methylprednisolone and Prednisone; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Vestibular Hypofunction, Binocular Vision Abnormalities, Reduced Vision
Interventions: StableEyes: Incremental Vestibulo-Ocular Reflex Adaptation (IVA); Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Diabetes
Interventions: BMS-903452, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Miramar, Florida • Austin, Texas

Conditions: No Evidence of Disease, BRCA1 Syndrome, BRCA2 Syndrome, Hereditary Female Breast Carcinoma, Hereditary Ovarian Carcinoma
Interventions: questionnaire administration, survey administration, counseling intervention, educational intervention; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 493 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2027
U.S. locations: 3
States / cities: Duarte, California • Los Angeles, California • Sylmar, California

Conditions: Urinary Bladder, Overactive
Interventions: VESIcare®, placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 739 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 65
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Atherton, California + 60 more

Conditions: Asthma
Interventions: BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, BD MDI 320 μg, Open-label Symbicort TBH 320/9 μg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 645 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 66
States / cities: Chandler, Arizona • Tucson, Arizona • Bakersfield, California + 56 more

Conditions: Diabetic Peripheral Neuropathy
Interventions: Tanezumab, placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 48
States / cities: Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 34 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Atorvastatin, Placebo (for atorvastatin); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 20
States / cities: Mesa, Arizona • Tucson, Arizona • Los Angeles, California + 14 more

Conditions: Overweight and Obesity
Interventions: MM-based MI, healthy education; Behavioral · Other
Lead sponsor: Michigan State University; Other
Eligibility: 3 Years to 11 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
Interventions: Omadacycline Oral Tablet, Placebo; Drug
Lead sponsor: Paratek Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 17
States / cities: Stanford, California • Washington D.C., District of Columbia • Clearwater, Florida + 14 more

Conditions: Immune Thrombocytopenia
Interventions: Rilzabrutinib, Placebo; Drug
Lead sponsor: Principia Biopharma, a Sanofi Company; Industry
Eligibility: 10 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Torrance, California + 13 more

Conditions: Anemia
Interventions: Lenalidomide, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 7
States / cities: Los Angeles, California • Centralia, Illinois • Lebanon, New Hampshire + 4 more

Conditions: Drug-Resistant Focal Epilepsy
Interventions: Implantable minimaly invasive brain stimulator; Device
Lead sponsor: Precisis US, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Weight Loss
Interventions: Standard Behavioral Weight Loss plus Non-Weight-Related VR app, Standard Behavioral Weight Loss plus Weight-Related VR app; Behavioral
Lead sponsor: California Polytechnic State University-San Luis Obispo; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Luis Obispo, California

Conditions: Renal Impairment
Interventions: RO7079901; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 2 more

Conditions: Burn Out, Student Burnout, Physician Assistant Student Burnout
Interventions: Reflective Writing Workshop Sessions; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Trauma, Post-Traumatic Stress Disorder
Interventions: Trauma Systems Therapy (TST), Treatment as Usual (TAU); Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 7 Years to 17 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Neoplasms, Mass Screening
Interventions: Patient intervention, PCP intervention; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years to 49 Years
Enrollment: 536 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure
Interventions: Polypill, Control Rx; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Overweight, Obesity
Interventions: Active and Healthy Families; Behavioral
Lead sponsor: University of California, Berkeley; Other
Eligibility: 5 Years to 12 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Pittsburg, California • San Pablo, California

Conditions: Ulcerative Colitis, Crohn's Disease
Interventions: Not listed
Lead sponsor: Dallas VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Trial To Evaluate the Efficacy of Intravenous Iron in Older Adults With Unexplained Anemia

Can Prophylactic Foraminotomy Prevent C5 Palsy

Increasing Optimal Use of HPV Vaccination in Primary Care

Cyclosporine Vs Steroids in DRESS

Visual Influences on Vestibular Adaptation

Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)

Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer

A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)

A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)

A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

The Feasibility and Preliminary Efficacy of the Mindful-Healthy Family Intervention With Rural Families

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q

EASEE® System Pivotal Study for the United States of America

A Virtual-reality Based Approach to Improve Behavioral Weight Management Outcomes

A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901

Trial to Evaluate the Efficacy of a Manualized Reflective Writing Program for Clinical Phase Physician Assistant (PA) Students.

Helping Children With Trauma

Preventing Early-Onset Colorectal Cancer in the VA

Polypill Strategy for Heart Failure With Reduced Ejection Fraction

Impact of Active and Healthy Families

Exacerbating Factors in Inflammatory Bowel Disease